IL279937A - CD38 antibody variants and their uses - Google Patents
CD38 antibody variants and their usesInfo
- Publication number
- IL279937A IL279937A IL279937A IL27993721A IL279937A IL 279937 A IL279937 A IL 279937A IL 279937 A IL279937 A IL 279937A IL 27993721 A IL27993721 A IL 27993721A IL 279937 A IL279937 A IL 279937A
- Authority
- IL
- Israel
- Prior art keywords
- variants
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697730P | 2018-07-13 | 2018-07-13 | |
| US201962848874P | 2019-05-16 | 2019-05-16 | |
| PCT/EP2019/069028 WO2020012036A1 (en) | 2018-07-13 | 2019-07-15 | Variants of cd38 antibody and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL279937A true IL279937A (en) | 2021-03-01 |
Family
ID=67396922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279937A IL279937A (en) | 2018-07-13 | 2021-01-04 | CD38 antibody variants and their uses |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20200017600A1 (enExample) |
| EP (1) | EP3820900A1 (enExample) |
| JP (2) | JP7526717B2 (enExample) |
| KR (1) | KR20210031932A (enExample) |
| CN (2) | CN120865412A (enExample) |
| AU (1) | AU2019300223A1 (enExample) |
| BR (1) | BR112020026432A2 (enExample) |
| CA (1) | CA3106146A1 (enExample) |
| CL (1) | CL2021000066A1 (enExample) |
| CO (1) | CO2021001544A2 (enExample) |
| CR (1) | CR20210081A (enExample) |
| DO (2) | DOP2021000006A (enExample) |
| EC (1) | ECSP21010092A (enExample) |
| IL (1) | IL279937A (enExample) |
| MA (1) | MA53122A (enExample) |
| MX (1) | MX2020013631A (enExample) |
| MY (1) | MY205398A (enExample) |
| PE (1) | PE20211858A1 (enExample) |
| PH (1) | PH12021550054A1 (enExample) |
| SG (1) | SG11202012993SA (enExample) |
| TW (1) | TW202019518A (enExample) |
| WO (1) | WO2020012036A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| KR20210031932A (ko) * | 2018-07-13 | 2021-03-23 | 젠맵 에이/에스 | Cd38 항체의 변이체 및 그의 용도 |
| PE20230113A1 (es) * | 2020-01-16 | 2023-01-27 | Genmab As | Formulaciones de anticuerpos anti-cd38 y usos de las mismas |
| IL298632A (en) * | 2020-06-02 | 2023-01-01 | Biocytogen Pharmaceuticals Beijing Co Ltd | Non-human animals genetically modified with a common light chain immunoglobulin locus |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| WO2023044346A2 (en) | 2021-09-14 | 2023-03-23 | Ausper Biopharma Co., Ltd. | Vaccines for coronavirus prevention and treatment |
| WO2023045859A1 (zh) * | 2021-09-23 | 2023-03-30 | 非同（成都）生物科技有限公司 | Cd38单克隆抗体及其应用 |
| JP2024540304A (ja) | 2021-11-03 | 2024-10-31 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体による治療におけるコルチコステロイドの減少 |
| CN114409788B (zh) * | 2022-03-04 | 2022-10-04 | 四川大学华西医院 | 抗cd38的抗体及其应用 |
| EP4612177A1 (en) | 2022-10-31 | 2025-09-10 | Genmab A/S | Cd38 antibodies and uses thereof |
| AU2023412139A1 (en) * | 2022-12-21 | 2025-06-19 | Sound Biopharmaceuticals Co. Ltd. | Cd38 monoclonal antibody and use thereof |
| TW202440636A (zh) * | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
| CN120965865A (zh) * | 2025-10-15 | 2025-11-18 | 内蒙古盛健生物科技有限责任公司 | 一种用于特异性治疗奶山羊羔羊口疮的抗体及其应用 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
| US835A (en) | 1838-07-12 | X i i i x | ||
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0486622B1 (en) | 1989-08-09 | 1998-11-04 | Rhomed, Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| IL144084A0 (en) | 1999-02-03 | 2002-05-23 | Biosante Pharmaceuticals Inc | Therapeutic calcium phosphate particles and methods of manufacture and use |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| JPWO2002030954A1 (ja) | 2000-10-06 | 2004-02-19 | 協和醗酵工業株式会社 | 抗体を精製する方法 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| PT1523496E (pt) | 2002-07-18 | 2011-09-29 | Merus B V | Produção de misturas de anticorpos de forma recombinante |
| NZ586780A (en) | 2005-03-23 | 2012-02-24 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR20150139636A (ko) | 2005-10-12 | 2015-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| EA016609B1 (ru) | 2005-11-28 | 2012-06-29 | Генмаб А/С | Рекомбинантные моновалентные антитела и способы их получения |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP3753576A1 (en) | 2006-09-26 | 2020-12-23 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| AU2008265984B2 (en) | 2007-06-21 | 2014-07-17 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| MX2011006416A (es) | 2008-12-19 | 2011-07-12 | Macrogenics Inc | Diacuerpos covalentes y sus usos. |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR20120027055A (ko) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| EP2507381A4 (en) | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| CA2796181C (en) | 2010-04-20 | 2023-01-03 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
| RS59769B1 (sr) * | 2010-06-09 | 2020-02-28 | Genmab As | Antitela protiv humanog cd38 |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| MX340556B (es) | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| EP2729496B8 (en) * | 2011-07-06 | 2017-10-18 | Genmab A/S | Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| ES2816078T3 (es) | 2011-12-20 | 2021-03-31 | Medimmune Llc | Polipéptidos modificados para armazones de anticuerpo biespecífico |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| ES2740749T3 (es) | 2012-04-20 | 2020-02-06 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| AU2013285355A1 (en) * | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| JP2015527366A (ja) | 2012-08-20 | 2015-09-17 | グリックニック インコーポレイテッド | 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子 |
| US20150353636A1 (en) | 2013-01-10 | 2015-12-10 | Genmab B.V. | Human igg1 fc region variants and uses thereof |
| JP6399560B2 (ja) | 2013-03-14 | 2018-10-03 | トランスレイト バイオ， インコーポレイテッド | ｍＲＮＡによってコードされる抗体を送達するための方法及び組成物 |
| DK2972360T3 (en) | 2013-03-15 | 2018-05-22 | Translate Bio Inc | SYNERGISTIC IMPROVEMENT OF DELIVERY OF NUCLEIC ACIDS THROUGH MIXED FORMULATIONS |
| LT3027642T (lt) * | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| BR112016023948A2 (pt) | 2014-04-16 | 2018-01-30 | Ucb Biopharma Sprl | proteínas fc multiméricas |
| ES3031941T3 (en) * | 2015-05-26 | 2025-07-14 | Univ Ramot | Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes |
| PT3313441T (pt) * | 2015-06-24 | 2024-05-07 | Janssen Biotech Inc | Modulação imunitária e tratamento de tumores sólidos com anticorpos que se ligam especificamente a cd38 |
| WO2017093447A1 (en) * | 2015-12-01 | 2017-06-08 | Genmab B.V. | Anti-death receptor antibodies and methods of use thereof |
| SMT202200252T1 (it) | 2015-12-22 | 2022-07-21 | Modernatx Inc | Composti e composizioni per il rilascio intracellulare di agenti |
| US20190022247A1 (en) | 2015-12-30 | 2019-01-24 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| MX2018016389A (es) | 2016-06-30 | 2019-08-16 | Arbutus Biopharma Corp | Composiciones y metodos para suministro de arn mensajero. |
| US10669344B2 (en) | 2016-08-12 | 2020-06-02 | Janssen Biotech, Inc. | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions |
| AU2017384276B9 (en) | 2016-12-21 | 2020-11-26 | F. Hoffmann-La Roche Ag | In vitro glycoengineering of antibodies |
| US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| AU2017381657B2 (en) | 2016-12-21 | 2020-07-23 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of antibodies |
| CN110100007B (zh) | 2016-12-21 | 2024-05-28 | 豪夫迈·罗氏有限公司 | 用于体外糖工程化抗体的酶的再使用 |
| KR20210031932A (ko) * | 2018-07-13 | 2021-03-23 | 젠맵 에이/에스 | Cd38 항체의 변이체 및 그의 용도 |
-
2019
- 2019-07-15 KR KR1020217003848A patent/KR20210031932A/ko not_active Ceased
- 2019-07-15 PE PE2021000038A patent/PE20211858A1/es unknown
- 2019-07-15 JP JP2021500814A patent/JP7526717B2/ja active Active
- 2019-07-15 AU AU2019300223A patent/AU2019300223A1/en active Pending
- 2019-07-15 US US16/512,206 patent/US20200017600A1/en not_active Abandoned
- 2019-07-15 CA CA3106146A patent/CA3106146A1/en active Pending
- 2019-07-15 MA MA053122A patent/MA53122A/fr unknown
- 2019-07-15 BR BR112020026432-6A patent/BR112020026432A2/pt unknown
- 2019-07-15 WO PCT/EP2019/069028 patent/WO2020012036A1/en not_active Ceased
- 2019-07-15 TW TW108124908A patent/TW202019518A/zh unknown
- 2019-07-15 EP EP19742548.1A patent/EP3820900A1/en active Pending
- 2019-07-15 CN CN202511041049.6A patent/CN120865412A/zh active Pending
- 2019-07-15 CR CR20210081A patent/CR20210081A/es unknown
- 2019-07-15 SG SG11202012993SA patent/SG11202012993SA/en unknown
- 2019-07-15 MY MYPI2020006631A patent/MY205398A/en unknown
- 2019-07-15 CN CN201980047066.7A patent/CN112513082B/zh active Active
- 2019-07-15 MX MX2020013631A patent/MX2020013631A/es unknown
-
2020
- 2020-02-10 US US16/786,563 patent/US20200165352A1/en not_active Abandoned
-
2021
- 2021-01-04 IL IL279937A patent/IL279937A/en unknown
- 2021-01-08 CL CL2021000066A patent/CL2021000066A1/es unknown
- 2021-01-08 PH PH12021550054A patent/PH12021550054A1/en unknown
- 2021-01-11 DO DO2021000006A patent/DOP2021000006A/es unknown
- 2021-02-10 CO CONC2021/0001544A patent/CO2021001544A2/es unknown
- 2021-02-11 EC ECSENADI202110092A patent/ECSP21010092A/es unknown
-
2024
- 2024-01-23 US US18/420,021 patent/US20240317881A1/en active Pending
- 2024-03-26 JP JP2024048842A patent/JP2024075737A/ja active Pending
- 2024-10-25 DO DO2024000217A patent/DOP2024000217A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY205398A (en) | 2024-10-19 |
| CA3106146A1 (en) | 2020-01-16 |
| JP7526717B2 (ja) | 2024-08-01 |
| ECSP21010092A (es) | 2021-03-31 |
| SG11202012993SA (en) | 2021-02-25 |
| WO2020012036A1 (en) | 2020-01-16 |
| US20240317881A1 (en) | 2024-09-26 |
| DOP2021000006A (es) | 2021-03-15 |
| MX2020013631A (es) | 2021-03-25 |
| DOP2024000217A (es) | 2024-11-29 |
| MA53122A (fr) | 2021-05-19 |
| BR112020026432A2 (pt) | 2021-03-23 |
| US20200017600A1 (en) | 2020-01-16 |
| US20200165352A1 (en) | 2020-05-28 |
| CN112513082B (zh) | 2025-08-12 |
| TW202019518A (zh) | 2020-06-01 |
| CN112513082A (zh) | 2021-03-16 |
| KR20210031932A (ko) | 2021-03-23 |
| CN120865412A (zh) | 2025-10-31 |
| EP3820900A1 (en) | 2021-05-19 |
| CR20210081A (es) | 2021-06-24 |
| PH12021550054A1 (en) | 2021-09-27 |
| CL2021000066A1 (es) | 2021-05-28 |
| AU2019300223A1 (en) | 2021-01-07 |
| CO2021001544A2 (es) | 2021-03-08 |
| JP2024075737A (ja) | 2024-06-04 |
| PE20211858A1 (es) | 2021-09-21 |
| JP2021524276A (ja) | 2021-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279937A (en) | CD38 antibody variants and their uses | |
| IL276731A (en) | Antibodies against CD73 and methods of using them | |
| IL278821A (en) | Anti-SIRPA antibodies and methods of using them | |
| ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| ZA202300348B (en) | Anti-sortilin antibodies and methods of use thereof | |
| IL279648A (en) | Anti-SIRP-in-cell 1 antibodies and methods of using them | |
| SMT202300243T1 (it) | Anticorpi anti-tigit e relativi metodi d'uso | |
| SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
| IL289813A (en) | Antibody against tau and its use | |
| IL269077A (en) | Anti-gitr antibodies and methods of use thereof | |
| SG11202108403UA (en) | Anti-clec2d antibodies and methods of use thereof | |
| IL277212A (en) | Anti-KLK5 antibodies and methods of use | |
| IL280338A (en) | Anti-SIGLEC-5 antibodies and methods of using them | |
| IL290741A (en) | Antibodies against cd-96 and methods of using them | |
| IL289952A (en) | Anti-ms4a4a antibodies and methods of using them | |
| IL268568A (en) | TRAILshort antibody and methods of use | |
| SG11202007443XA (en) | Cd38 protein antibody and application thereof | |
| IL283884A (en) | Antibodies against il-36 and methods of using them | |
| IL273538A (en) | Anti-TRKB Monoclonal Antibodies and Methods of Use | |
| IL291461A (en) | Anti-alpha-synuclein antibodies and methods of using them | |
| IL274221A (en) | Antibodies to ANTI-APOC3 and methods of use | |
| IL279227A (en) | Anti-SIGLEC-7 antibodies and methods of using them | |
| ZA202002144B (en) | Antibodies and methods of use | |
| HK40048593A (en) | Variants of cd38 antibody and uses thereof |